Heat Biologics Revenue and Competitors

Location

$50.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Heat Biologics's estimated annual revenue is currently $7.5M per year.(i)
  • Heat Biologics's estimated revenue per employee is $258,621
  • Heat Biologics's total funding is $50.1M.

Employee Data

  • Heat Biologics has 29 Employees.(i)
  • Heat Biologics grew their employee count by -15% last year.

Heat Biologics's People

NameTitleEmail/Phone
1
VP, Chemistry and Manufacturing ControlsReveal Email/Phone
2
VP ResearchReveal Email/Phone
3
SVP Product Development and Portfolio StrategyReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Accounts Payable ManagerReveal Email/Phone
6
Senior Business Development AdvisorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is Heat Biologics?

Heat Biologics (Heat) is a clinical-stage company focused on the development and commercialization of its HS-System, a platform technology that offers a novel approach to treating cancer and other diseases by using live, modified cell lines to activate the immune system against specific defined targets. Heat is currently Phase I/II clinical trial with its first drug for patients with advanced non-small cell lung cancer.

keywords:N/A

$50.1M

Total Funding

29

Number of Employees

$7.5M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Heat Biologics News

2022-04-17 - Heat Biologics' New Biodefense Facility to Create 500 Kansas ...

The company falls under the umbrella of Heat Biologics, a clinical-stage biopharmaceutical company focused on biodefense assets. The project is...

2022-04-17 - Heat Biologics, behind $650M biodefense facility in Kansas ...

Morrisville biopharmaceutical firm Heat Biologics (NYSE: HTBX) has had a busy week. The company on Monday unveiled plans for one of its...

2022-04-17 - Heat Biologics (“NightHawk Biosciences”) Completes ...

Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics ... DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat...

2021-04-12 - HEAT BIOLOGICS, INC. Heat Biologics : Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021 Download as PDFApril 12, 2021 DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M290%N/A
#2
$4.3M29-9%N/A
#3
N/A2932%N/A
#4
$5.8M29-43%N/A
#5
$2M2916%N/A